Phase 2 Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults
Phase of Trial: Phase II
Latest Information Update: 25 Feb 2016
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SWAD
- 07 Jun 2017 Biomarkers information updated
- 19 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.